

# Index

## A

- Access and Cost of Patents, 165
- Accessibility
  - of abstract genomic data, 179, 180
  - of genomic databases, 182, 183
  - of research tools, 5, 153, 237
- Access of Human Genetic Resources and Benefit Sharing, 222
- Algorithms, 8, 172
  - computer, 82
  - mathematical, 41, 183
  - patenting of, 174, 175
- Analogies between Biotech and software, 191
- Andean Common System on Access to Genetic Resources, 217, 218
- Andean Pact, 217, 218, 222
- Animals as patentable Subject matter, 32–34
- Anticommons, 5, 141
- Association for Molecular Pathology v. Myriad Genetics, 48, 49
- Association for Molecular Pathology v. U.S.P.T.O., 44, 45

## B

- Bayh-Dole Act, 4, 24, 138, 149, 150
- Benefit sharing, 9, 15, 222–226, 243
- Bermuda principles, 180, 182, 241
- Best mode, 35, 60, 64, 98, 106
- Bilski Case, 42, 43, 46
- Bioinformatics, 1, 8, 170, 173, 175, 176, 189
  - databases, 8, 15, 171, 176, 192, 238, 247
  - definition of, 170
  - software, 171, 172, 177, 178, 185, 186, 239, 240
- Biotechnology, 1, 3, 10, 11, 15, 17, 20
  - as a patentable subject matter, 23, 24
  - in European Union, 67

- inventions, 2, 14
- patents, 22
- BRCA1 and BRCA2 genes, 6, 49, 157, 160, 161
- Budapest treaty, 85, 106, 126

## C

- Canadian Institute of Health Research (CIHR), 161
- Canavan Disease Case, 203–206
- Catalona case, 206
- Certificates of origin for (non-human) genetic resources, 226
- Chakrabarty Case, 31, 32
- Chemical inventions, 20, 229
- Commercialisation of Genetic Research, 237
- Commercialisation of human genetic material, 197
- Community resource projects, 181–183
- Compositions of matters, 25, 27
- Compulsory licensing, 100, 162, 166
- Consultative Group on International Agricultural Research (CGIAR), 221
- Convention on Biological diversity (CBD), 9, 222, 243
- Convention on the Unification of Certain Points of Substantive Law for Invention, 64
- Copyright, 8, 173, 176, 184, 239, 240
  - protection to software, 177, 178
- Court of Appeal for Federal Circuit (CAFC), 24, 46, 47

## D

- Databases, 188, 189, 237, 240
- Deposition of biological material, 126

Diagnostic gene patents, 5, 43, 47, 63, 164, 231

Diagnostic genetic testing, 163

Diagnostic tests, 39, 42, 142, 153, 157, 163

Differentiation, 13, 127

Dimminaco Case- Paving the Way for Biotechnology Patents in India, 100–102

Direct to Consumer campaign bypass physicians, 164

Divergence in Biotechnology Patent Practices, 22, 23

DNA sequences, 21, 38, 45, 46, 58, 60, 61, 105, 106, 144, 147, 154, 165, 174, 232

Draft substantive patent law treaty (SPLT), 4, 129

**E**

Enablement, 60–64, 77, 106

Essential biological processes, 67

European Biotechnology Directive, 67, 115

European Database Rights Directives, 174

Exceptions under TRIPS, 116, 117

Expressed Sequence Tags (ESTs), 5, 150

**F**

Free and open source software (FOSS), 183, 189

**G**

Gene fragments, 2, 4, 5, 21, 39, 40, 141, 142, 229, 231, 232, 236

Gene patents, 2, 3, 12, 13, 22, 37–39, 63, 99, 156, 160, 237

General Agreement on Tariffs and Trades (GATT), 112

negotiation, 123, 124

Gene sequencing, 2, 21, 38

Genetic information, 7, 8, 69, 79, 119, 155, 166, 179, 183, 205, 235, 238, 247

Genetic research, 4, 5, 9, 14, 15, 73, 137, 138, 142, 145, 153, 165, 198, 212, 236, 238, 240, 248

importance of patents in, 139

Genetic Resources- A Global Genetic Commons, 215

Genomic databases, 8, 15, 60, 238, 247

goals of, 179

Genomics, 1, 2, 22, 39, 60

Guidelines for the Examination in the European Patent Office, 2001 (EPO Guidelines), 66

**H**

HapMap project, 181, 182, 241

Harmonization, 4, 129, 246

obstacles in, 132

Harvard College Case (Harvard Oncomouse), 82, 94, 232

Havasupai case, 210–214, 249

Human Chimera and Humanoid, 34

Human gene, 2, 12, 13, 20, 36, 37, 79, 160, 196

Human Genetic Patents, 20

Human Genetic Resources, 9, 15, 196, 214, 224, 243

Human Genome as Common Heritage, 198

Human Genome Organisation (HUGO), 224, 225

Human Genome Project, 2, 7, 39, 169, 179, 186, 197, 240

**I**

Impact of patenting of genetic research tools on innovation, 144, 145

Impact of patents with broad scope on genetic research, 140

Implications of patents relating to genetic research tools for society, 143, 144

Importance of Patents in Genetic Research, 139

Indian Patent Act 1970, as amended in 1999, 2002 and 2005, 100

Indian Position on Benefit Sharing under Biological Diversity Act, 225

Industrial applicability, 2, 74

Informed consent, 15, 134, 200, 202, 204, 207, 208, 210–214, 243

Innovation and open development, 191, 192

Intellectual property rights (IPR), 1, 2, 8, 9, 11, 12, 14, 112, 124, 196, 199, 213, 229, 243

Interfaces, 175

International Depository Authority (IDA), 106, 107, 126

International patent regime, 3, 14, 233, 244

International Undertaking on Plant Genetic Resources (Undertaking), 214

Invention, 2, 8, 14, 22, 24, 50–53, 64, 71, 80, 100, 102, 245

Inventive step, 2, 21, 67, 71, 73, 104, 105, 113, 245

Isolated and purified genes, 46, 47, 215, 232

**L**

- Legal implications, 4, 13
- Life forms, 3, 20, 23, 25, 80, 216, 233
- Limitations of a license, 183
- Limitations on the Scope of Patentable Subject Matter, 28, 29

**M**

- Microbiological processes, 67, 99, 103, 115, 118, 119, 133, 108
- Microorganisms, 3, 14, 18, 20, 27, 32, 82, 90, 103, 117, 234
- Monsanto case, 94
- Moore case, 199, 200, 202, 206
- Morality, 3, 35, 77, 78, 81, 99, 107, 107
- Multi-cellular organisms, 67, 68
- Myriad Genetics Inc, 7, 46, 156, 158, 159
- Myriad's Patents on BRCA1 and BRCA2 Genes, 154, 155

**N**

- Non-Human genetic resource, 15, 219, 243, 249
- Non-obviousness, 2, 45, 50, 57–59, 97, 176
- Novelty, 2, 20, 50–53, 70, 97, 132, 245

**O**

- Open and Collaborative Databases importance of, 188
- Open Bio Good for Developing Countries, 192
- Open bio movement, 183, 186, 241
- Open biotechnology, 8, 15, 184, 186, 241, 242, 248
- Open source biotechnology, 8, 241
- Open standards, 188, 189
- Ordre public and morality, 3, 22, 77–80, 117, 118, 232, 234, 244
- Ownership of human genetic material, 8, 9, 195, 196, 249
- Ownership rights of research subjects, 15, 248

**P**

- Paris Convention, 112
- Patentability of biotechnology, 2, 65, 67, 123
  - in European Union, 64
  - in United States, 23
  - inventions in Canada, 80, 81
  - inventions in India, 99, 100
- Patentability of genetic research tools, 143
- Patentable subject matter, 2, 27, 32, 66–68, 81, 82
  - plants as, 31, 36
- Patent Cooperation Treaty (PCT), 126

- Patent eligible subject matters, 2, 4, 40, 42, 48
- Patent infringement, 25, 47, 93, 100, 149, 150, 152, 162, 246
- Patenting of ESTs and Reach through Claims, 144
- Patenting of genetic tests for diagnostic purposes, 153, 154
- Patent law, 2, 3, 14, 17, 20, 85, 127, 130, 240
- Patents rights, 79, 83, 91, 113, 140, 150, 152
- Patent thickets, 5, 141, 145, 191
- Phenotype data, 182
- Pioneer Hi-Bred case, 86
- Plant varieties, 89, 104, 120, 121, 235
- Policy Implications of Myriad's Patents on BRCA1 and BRCA2, 163, 164, 165
- Population genetics, 9
- Product of Nature Doctrine, 23, 29, 198
- Proteins, 1, 10, 38, 45
  - endotoxin, 63
  - therapeutic, 142

**Q**

- Quality of testing, 164

**R**

- Re Application of Abitibi Co, 82
- Researchers, 6, 7, 9, 13, 14, 138, 146, 165, 190, 198, 211
  - academic, 5, 9, 138
- Research exemptions and their scope, 147, 148
- Research subjects, 9, 196, 198, 207, 242
- Research tools, 5, 14, 39, 142, 248
- Royalty stacking, 5, 141

**S**

- Scope of the Patent Laws- Anything under the sun made by man, 28
- Single nucleotide polymers (SNPs), 5
  - consortium, 181, 190, 241
- Social implications, 12, 162
- Sovereign Control v. Open system, 220, 221
- Status of biotechnology patent in India, 108
- Statutory exception in developing countries, 152, 153
- Sui generis system, 116, 120

**T**

- The Biodiversity Act 2002, 218
- The European Patent Convention (EPC), 64, 123, 151, 173
- The Genome Research and Accessibility Act (GRAA), 156

- The International Bioethics Committee of UNESCO, 224
- The Ontario Health Insurance Plan (OHIP), 162
- Tightening of subject matter boundary, 42
- Traces of a Unified System of Patents for European Union, 64, 65
- Trade secrets protection, 178, 247
- Tradition Knowledge Digital library (TKDL), 192
- TRIPS agreement, 3, 4, 112, 115, 119, 235, 236, 246
- TRIPS plus agreement, 128
- U**
- UNESCO's Universal Declaration on the Human Genome and Human Rights, 1997, 197
- Unicellular Organisms *See* Microorganisms, 67
- United States National Bioethics Advisory Commission, 223
- University-industry relationship, 4, 138
- Utility, 2, 21, 39, 41, 45, 50, 54–57
- W**
- Welcome trust, 190
- World Intellectual Property Organization (WIPO), 4, 12, 129
- World Trade Organisation (WTO), 112, 133, 134
- Written description, 2, 35, 50, 60–62, 98, 126